Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab for Cognitive Function in RRMS
NCT01333358Phase 3Unknown
- Sponsor
- Central Texas Neurology Consultants
- Start
- May 2011
- Primary completion
- Dec 2013
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 3 trial of alemtuzumab in relapsing-remitting multiple sclerosis (RRMS), sponsored by Central Texas Neurology Consultants. Status: unknown.
02
Drugs
alemtuzumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT01333358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01333358.